About Us
Sequenom is committed to providing the best genomic and genetic analysis solutions for the research and molecular diagnostic markets.
Sequenom, Inc.
Sequenom, Inc. (NASDAQ: SQNM) designs, develops, manufactures and markets innovative technology, instrumentation and tests that target and serve discovery and clinical research, and clinical molecular diagnostics markets. Applications include translational research, oncology, agricultural genomics and in vitro diagnostics for prenatal and retinal disorders.
Technologies employed include mass spectrometry and second generation DNA sequencing. The company's proprietary MassARRAY® system is a high-performance mass spectrometry based DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations. The system delivers reliable and specific data from biological samples and from genetic target material that is only available in trace amounts.
The company was founded in 1994 and employs over 550 employees worldwide. Sequenom is headquartered in San Diego, CA.
Sequenom is committed to improving healthcare through revolutionary genetic analysis solutions.
Sequenom Center for Molecular Medicine, LLC
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. Branded under the names SensiGene®, MaterniT21™ PLUS, and RetnaGene™, these molecular genetic laboratory tests provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists, retina specialists and ophthalmologists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.